Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ATHEROSCLEROSIS: HOW TO START UP A "COUNT DOWN" CLOCK? WE DON'T KNOW, WE CAN NOT OR WE DO NOT WANT?

https://doi.org/10.20996/1819-6446-2011-7-1-49-56

Full Text:

Abstract

Clinical cases of long-term use of rosuvastatin are presented with an estimation of its effect on the soft end (lipid profile) and hard end (number of heart attacks, strokes, heart failure, hospitalization for cardiovascular causes) points are given. The results of studies on rosuvastatin (ASTEROID, CORONA, METEOR, ORION, COSMOS) are presented. Clinical guidelines on the management of patients with stable ischemic heart disease are considered on the example of COURAGE trial.

About the Author

L. N. Malay
Medical sanitary unit of the Federal Security Service Directorate in Khabarovsk Territory
Russian Federation


References

1. Matusova E.I. Aggressive tactics of statin treatment in patients at high risk of cardiovascular events. Serdtse 2008;7(6):349-356. Russian (Матусова Е.И. Агрессивная тактика лечения статинами больных с высоким риском сердечно-сосудистых событий. Сердце 2008;7(6):349-356).

2. National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika 2007;6 (6) Prilozhenie 3: 1-32. Russian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007;6 (6) Приложение 3: 1-32).

3. Malay L.A., Sharykin B.V., Miroshnichenko A.N. et al. Statin treatment: myths and reality. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(3): 95-100. Russian (Малай Л.Н., Шарыкин Б.В., Мирошниченко А.Н. и др. Мифы и реальность терапии статинами. Кардиоваскулярная терапия и профилактика 2008; 7(3): 95-100).

4. Nissen S.Е., Nicholls S.J., Sipahi I., Libby P. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13):1556-1565.

5. Zateyshchikov D.A. Algorithm for use of statins. Spravochnik poliklinicheskogo vracha 2008;7:2-9. Russian (Затейщиков Д.А. Алгоритм назначения статинов. Справочник поликлинического врача 2008;7:2-9).

6. Bubnova M.G. Statin therapy in atherosclerosis prevention: modern strategy and tactics. Kardiovaskulyarnaya terapiya i profilaktika 2009; 8(3):94-102. Russian (Бубнова М.Г. Статины в профилактической терапии атеросклероза: современная стратегия и тактика назначения. Кардиоваскулярная терапия и профилактика 2009; 8(3):94-102).

7. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in eldery individuals at of vascular disease (PROSPER) randomised trial. Lancet 2002; 360: 1623-30.

8. Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005; 7(6): 357: 1059–69.

9. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007;194(1):1-45.

10. Maggioni A.P. SCOUT trial reports on the safety profile of sibutramine in patients with cardiovascular diseases. Phys Sportsmed 2009;37(3):95-7.

11. Bylova N.A. Review of foreign publications. Serdtse 2010; 9(2):128-132. Russian (Былова Н.А. Об-зор зарубежных публикаций. Сердце 2010; 9(2):128-132).

12. Crouse J.R. III, Grobbee D.E., O'Leary D.H. et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis — the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004; 18: 231-238.

13. Underhill H.R., Yuan C., Zhao X.Q., Kraiss L.W. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008; 155(3): 5841–5848.

14. Takayama T., Hiro T., Yamagishi M. et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009;73(11):2110-7.

15. Boden W., O'Rourke R., Teo K. et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1-14.

16. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28:2375-414.

17. Martsevich S.Yu., Kutishenko N.P. Could evidence-based medicine results be reproduced in real-world clinical practice? Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(3):4-7. Russian (Марцевич С.Ю., Кутишенко Н.П. Возможно ли воспроизвести достижения доказательной медицины в реальной клинической практике? Кардиоваскулярная терапия и профилактика 2008; 7(3):4-7).

18. Martsevich S.Yu. News of the Congress of the American Heart Association. Rational Pharmacother Card 2007;5:39-44. Russian (Марцевич С.Ю. Новости конгресса Американской кардиологической ассоциации. РФК 2007; 3(5): 121-2).

19. Underhill H.R., Yuan C., Zhao X.Q. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;155(3):584.e1-8.

20. Palmer S.J., Brady A.J., Ratcliffe A.E. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003; 57(9): 792-800.

21. Benner J.S., Smith T.W., Klingman D. et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Heaith. 2005; 8 (6): 618-628.


For citation:


Malay L.N. ATHEROSCLEROSIS: HOW TO START UP A "COUNT DOWN" CLOCK? WE DON'T KNOW, WE CAN NOT OR WE DO NOT WANT? Rational Pharmacotherapy in Cardiology. 2011;7(1):49-56. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-49-56

Views: 368


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)